Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 38Radiotherapy 21Radiosurgery 21Irinotecan 11Cyclophosphamide 11Radiation 10Magnetic Resonance Spectroscopy 10Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9Filgrastim 8Carboplatin 8pembrolizumab 7Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Watchful Waiting × Clear all
NCT01122888 2015-04-28

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1 Terminated
41 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡